Literature DB >> 10881884

Symptomless infection with Ebola virus.

A G Baxter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10881884     DOI： 10.1016/S0140-6736(00)02394-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Understanding the dynamics of Ebola epidemics.

Authors:  J Legrand; R F Grais; P Y Boelle; A J Valleron; A Flahault
Journal:  Epidemiol Infect       Date:  2006-09-26       Impact factor: 2.451

3.  Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis.

Authors:  Lei Zhang; Hao Wang; Yi-qing Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

4.  Can Ebola virus become endemic in the human population?

Authors:  Gary Wong; George F Gao; Xiangguo Qiu
Journal:  Protein Cell       Date:  2016-01       Impact factor: 14.870
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.